1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Qiagen N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
Delayed Nyse  -  04:01 2022-06-24 pm EDT
46.63 USD   +4.02%
06/23Qiagen N.V. to Seek M&A
CI
06/23TRANSCRIPT : Qiagen N.V. - Shareholder/Analyst Call
CI
06/17TCS Partners with QIAGEN in Driving its Cloud Transformation Strategy
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Qiagen sees no immediate impact from global supply bottlenecks

04/28/2022 | 05:29am EDT
FILE PHOTO: Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit a testing company Qiagen, in Hilden

FRANKFURT, April 28 (Reuters) - U.S.-German biotechnology company Qiagen NV said on Thursday it was not currently affected by the latest supply chain bottlenecks as it had already been stockpiling supplies at its production facilities amid pandemic-related uncertainties.

The company, which makes genetic diagnostics kits including COVID-19 tests, can rely on its existing supplies for a few more weeks despite bottlenecks due to the recent pandemic outbreak in China, finance chief Roland Sackers told a news conference.

"Of course, in the medium term, we are also dependent on components that have to arrive. But the lockdown, especially in Shanghai, must be resolved soon," Sackers said.

"Thank goodness we don't have any products now that are highly perishable," the CFO added.

Qiagen's COVID-19 tests had helped it to boost sales in 2020-2021 and recover from a tough 2019 with profit warnings, a slump in China business and a CEO departure, but it expects a sales decline in 2022 as coronavirus testing demand wears down.

On Tuesday, Qiagen raised its 2022 sales guidance, saying it now expected the figure to drop by 6% or less compared to its previous forecast for a drop of around 8% - the first decline in a full year since Qiagen has been listed.

The company said the reason for the upgrade was its stronger-than-expected first-quarter performance as investments in its non-COVID-19 product range were starting to pay off.

"The growth was driven by our very broad portfolio. It really wasn't one particular product that we were able to highlight," Sackers said on Thursday.

(Reporting by Zuzanna Szymanska, Editing by Miranda Murray and Tomasz Janowski)


© Reuters 2022
All news about QIAGEN N.V.
06/23Qiagen N.V. to Seek M&A
CI
06/23TRANSCRIPT : Qiagen N.V. - Shareholder/Analyst Call
CI
06/17TCS Partners with QIAGEN in Driving its Cloud Transformation Strategy
AQ
06/16Tata Consultancy Services Bags New Contract from Germany's QIAGEN
MT
06/10QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
06/08QIAGEN NV : Jefferies reaffirms its Neutral rating
MD
06/08TRANSCRIPT : QIAGEN N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2..
CI
06/03Test makers target monkeypox market as cases surge
RE
06/01U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infe..
BU
05/26QIAGEN NV : Gets a Buy rating from Deutsche Bank
MD
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2022 2 093 M - -
Net income 2022 387 M - -
Net Debt 2022 497 M - -
P/E ratio 2022 27,3x
Yield 2022 -
Capitalization 10 606 M 10 606 M -
EV / Sales 2022 5,31x
EV / Sales 2023 4,97x
Nbr of Employees 6 000
Free-Float 98,2%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 46,63 $
Average target price 56,32 $
Spread / Average Target 20,8%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Vice President-Finance
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Lezette Young Manager-Compliance & Legal
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-16.10%10 606
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371